title: Prophylactic use of ofloxacin in granulocytopenic patients with hematological malignancies during post-remission chemotherapy.
abstract: The prophylactic efficacy of ofloxacin (OFLX) therapy was evaluated in 51 granulocytopenic episodes in 22 patients with hematological malignancies during post-remission chemotherapy in a prospective, randomized, controlled trial. Oral administration of OFLX plus amphotericin-B (AMPH) and polymyxin-B (PL) reduced episodes of fever and infection more than did the control regimen with PL and AMPH alone (p less than 0.01), and the reduction in the incidence of infection was evident even in patients showing severe granulocytopenia (p less than 0.01). Furthermore, the first fever after the onset of granulocytopenia in the OFLX regimen developed later than that in the control regimen (p less than 0.05). Clinically, the prophylactic efficacy was 92% for the OFLX regimen and 40% for the control regimen (p less than 0.01). These findings suggest that OFLX is a promising prophylactic agent following post-remission chemotherapy. Patient hemomyelogram findings similar to those of patients with other malignancies may imply that OFLX is widely effective in granulocytopenic patients taking aggressive chemotherapy.
authors.affiliation: First Department of Internal Medicine, Fukui Medical School, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Tsutani
authors.forename: S
authors.initials: S
authors.lastname: Imamura
authors.forename: T
authors.initials: T
authors.lastname: Ueda
authors.forename: H
authors.initials: H
authors.lastname: Yoshida
authors.forename: H
authors.initials: H
authors.lastname: Iwasaki
authors.forename: T
authors.initials: T
authors.lastname: Fukushima
authors.forename: T
authors.initials: T
authors.lastname: Yoshimura
authors.forename: S
authors.initials: S
authors.lastname: Toyooka
authors.forename: T
authors.initials: T
authors.lastname: Nakamura
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000009:adverse effects; D001424:Bacterial Infections / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D015242:Ofloxacin